Bitcoin price today: falls to 2-week low below $113k ahead of Fed Jackson Hole
Investing.com - H.C. Wainwright raised its price target on Bionano Genomics (NASDAQ:BNGO) to $11.00 from $10.00 on Monday, while maintaining a Buy rating on the stock following the company’s second-quarter financial results. According to InvestingPro data, analyst targets for BNGO range from $8.00 to $10.00, with a consensus recommendation of 2.33 (Buy).
Bionano Genomics reported total revenue of $6.7 million for the second quarter of 2025, representing a 13% year-over-year decline but showing sequential growth from $6.5 million in the first quarter. The company’s gross margin improved to over 50% during the quarter. InvestingPro analysis reveals the company’s trailing twelve-month revenue stands at $27.43 million, with an EBITDA of -$37.85 million, highlighting ongoing operational challenges.
The optical genome mapping (OGM) company sold 7,233 nanochannel array flowcells in the second quarter, up 17% from 6,165 flowcells in the same period last year. Bionano also installed seven new OGM systems and reactivated eight others, bringing its installed base to 378 at the end of the quarter, compared to 363 a year ago.
Bionano reported a net loss of $6.9 million, or $1.99 per share, which was less than H.C. Wainwright’s estimated loss of $8.1 million due to reduced operating expenses and improved capital efficiency.
The company maintained its full-year 2025 revenue guidance of $26-30 million, including third-quarter revenue of $6.7-7.2 million, and increased its new OGM installation expectations for fiscal year 2025 to 20-25 systems, up from its previous forecast of 15-20. InvestingPro subscribers can access 11 additional ProTips and a comprehensive Research Report covering BNGO’s financial health, market position, and growth prospects.
In other recent news, Bionano Genomics reported a 13% decline in its Q2 2025 revenue, bringing in $6.7 million compared to the same period last year. This decrease in revenue comes despite improvements in the company’s gross margin and a reduction in operating expenses. The financial results have raised concerns among investors, as reflected in the stock’s performance in aftermarket trading. Analysts and investors alike are closely monitoring these developments to gauge the company’s future trajectory. The earnings report is a significant indicator of the company’s current financial health and operational efficiency. These recent developments highlight the challenges Bionano Genomics faces in maintaining its revenue growth. The company’s financial performance will likely continue to be a focal point for investors and analysts in the coming quarters.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.